Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

Posted by Jessica Moore on Feb 13th, 2025

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF – Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 642,400 shares, a decline of 55.7% from the January 15th total of 1,450,700 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 6,424.0 days.

Wall Street Analyst Weigh In

Separately, Barclays upgraded Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research note on Wednesday, January 8th.

Check Out Our Latest Report on BIOVF

Swedish Orphan Biovitrum AB (publ) Stock Performance

Shares of OTCMKTS:BIOVF remained flat at $30.48 on Thursday. The company’s 50-day moving average is $28.63 and its 200 day moving average is $28.80. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49. The stock has a market capitalization of $10.85 billion, a PE ratio of 51.66 and a beta of 0.53. Swedish Orphan Biovitrum AB has a 1-year low of $22.87 and a 1-year high of $32.25.

About Swedish Orphan Biovitrum AB (publ)

(Get Free Report)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.